Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 394913, 5 pages
http://dx.doi.org/10.1155/2010/394913
Research Article

Repeated Intraperitoneal 𝛼 -Radioimmunotherapy of Ovarian Cancer in Mice

1Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden
2PET and Cyclotron Unit, Rigshospitalet, Copenhagen, Denmark

Received 15 April 2009; Accepted 1 September 2009

Academic Editor: Maurie M. Markman

Copyright © 2010 Jörgen Elgqvist et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. McQuarrie, J. R. Mercer, A. Syme, M. R. Suresh, and G. G. Miller, “Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 7, pp. 29–34, 2004. View at Google Scholar
  2. M. L. Janssen, W. Pels, L. F. Massuger et al., “Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide,” International Journal of Gynecological Cancer, vol. 13, no. 5, pp. 607–613, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. P. E. Borchardt, S. M. Quadri, R. S. Freedman, and H. M. Vriesendorp, “Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis,” Cancer Biotherapy and Radiopharmaceuticals, vol. 15, no. 1, pp. 53–64, 2000. View at Google Scholar · View at Scopus
  4. C. Grana, M. Bartolomei, D. Handkiewicz et al., “Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with Y90-biotin?” Gynecologic Oncology, vol. 93, no. 3, pp. 691–698, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. R. F. Meredith, R. D. Alvarez, E. E. Partridge et al., “Intraperitoneal radioimmuno-chemotherapy of ovarian cancer: a phase I study,” Cancer Biotherapy and Radiopharmaceuticals, vol. 16, pp. 305–315, 2001. View at Google Scholar
  6. M.-A. Mahe, P. Fumoleau, M. Fabbro et al., “A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma,” Clinical Cancer Research, vol. 5, no. 10, supplement, pp. 3249–3253, 1999. View at Google Scholar · View at Scopus
  7. A. A. Epenetos, V. Hird, H. Lambert, P. Mason, and C. Coulter, “Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy,” International Journal of Gynecological Cancer, vol. 10, supplement 1, pp. 44–46, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. R. D. Alvarez, E. E. Partridge, M. B. Khazaeli et al., “Intraperitoneal radioimmunotherapy of ovarian cancer with L177u-CC49: a phase I/II study,” Gynecologic Oncology, vol. 65, no. 1, pp. 94–101, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. R. D. Alvarez, W. K. Huh, M. B. Khazaeli et al., “A phase I study of combined modality Y90ttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer,” Clinical Cancer Research, vol. 8, no. 9, pp. 2806–2811, 2002. View at Google Scholar · View at Scopus
  10. J. S. W. Stewart, V. Hird, D. Snook et al., “Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer,” Journal of Clinical Oncology, vol. 8, no. 12, pp. 1941–1950, 1990. View at Google Scholar · View at Scopus
  11. R. H. Verheijen, L. F. Massuger, B. B. Benigno et al., “Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission,” Journal of Clinical Oncology, vol. 24, no. 4, pp. 571–578, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. A. L. Oei, R. H. Verheijen, M. V. Seiden et al., “Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival,” International Journal of Cancer, vol. 120, no. 12, pp. 2710–2714, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. H. Andersson, J. Elgqvist, G. Horvath et al., “Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model,” Clinical Cancer Research, vol. 9, no. 10, pp. 3914–3921, 2003. View at Google Scholar · View at Scopus
  14. H. Andersson, S. Lindegren, T. Bäck, L. Jacobsson, G. Leser, and G. Horvath, “Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing A211t-labelled monoclonal antibody MOv18,” Anticancer Research, vol. 20, no. 1, pp. 459–462, 2000. View at Google Scholar · View at Scopus
  15. H. Andersson, S. Lindegren, T. Bäck, L. Jacobsson, G. Leser, and G. Horvath, “The curative and palliative potential of the monoclonal antibody MOv18 labelled with A211t in nude mice with intraperitoneally growing ovarian cancer xenografts: a long-term study,” Acta Oncologica, vol. 39, no. 6, pp. 741–745, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Andersson, S. Palm, S. Lindegren et al., “Comparision of the therapeutic efficacy of A211t- and I131-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer,” Anticancer Research, vol. 21, no. 1, pp. 409–412, 2001. View at Google Scholar · View at Scopus
  17. J. Elgqvist, H. Andersson, T. Bäck et al., “Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with A211t- labeled monoclonal antibody MX35,” Journal of Nuclear Medicine, vol. 46, no. 11, pp. 1907–1915, 2005. View at Google Scholar · View at Scopus
  18. J. Elgqvist, H. Andersson, P. Bernhardt et al., “Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with A211t-MX35F(ab)2,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 4, pp. 1228–1237, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. Elgqvist, H. Andersson, T. Bäck et al., “α-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose,” Journal of Nuclear Medicine, vol. 47, no. 8, pp. 1342–1350, 2006. View at Google Scholar · View at Scopus
  20. J. Elgqvist, P. Bernhardt, R. Hultborn et al., “Myelotoxicity and RBE of A211t-conjugated monoclonal antibodies compared with T99mc-conjugated monoclonal antibodies and C60o irradiation in nude mice,” Journal of Nuclear Medicine, vol. 46, no. 3, pp. 464–471, 2005. View at Google Scholar · View at Scopus
  21. T. Bäck, H. Andersson, C. R. Divgi et al., “A211t radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an α-emitter in vivo,” Journal of Nuclear Medicine, vol. 46, no. 12, pp. 2061–2067, 2005. View at Google Scholar · View at Scopus
  22. S. Lindegren, T. Bäck, and H. J. Jensen, “Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields,” Applied Radiation and Isotopes, vol. 55, no. 2, pp. 157–160, 2001. View at Publisher · View at Google Scholar
  23. B. W. Yin, R. Kiyamova, R. Chua et al., “Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas,” Cancer Immunity, vol. 8, pp. 3–11, 2008. View at Google Scholar
  24. S. C. Rubin, L. Kostakoglu, C. Divgi et al., “Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX 35 in patients with epithelial ovarian cancer,” Gynecologic Oncology, vol. 51, no. 1, pp. 61–66, 1993. View at Publisher · View at Google Scholar · View at PubMed
  25. S. Lindegren, H. Andersson, T. Bäck, L. Jacobsson, B. Karlsson, and G. Skarnemark, “High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate,” Nuclear Medicine and Biology, vol. 28, no. 1, pp. 33–39, 2001. View at Publisher · View at Google Scholar
  26. T. C. Hamilton, R. C. Young, W. M. McKoy et al., “Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors,” Cancer Research, vol. 43, no. 11, pp. 5379–5389, 1983. View at Google Scholar
  27. T. Lindmo, E. Boven, F. Cuttitta, J. Fedorko, and P. A. Bunn, “Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess,” Journal of Immunological Methods, vol. 72, no. 1, pp. 77–89, 1984. View at Publisher · View at Google Scholar
  28. J. Elgqvist, H. Andersson, T. Bäck et al., “Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with A211t-MX35F(ab)2: therapeutic efficacy and myelotoxicity,” Nuclear Medicine and Biology, vol. 33, no. 8, pp. 1065–1072, 2006. View at Publisher · View at Google Scholar · View at PubMed
  29. H. Andersson, E. Cederkrantz, T. Bäck et al., “Intraperitoneal α-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of A211t-MX35F(ab)2—a phase I study,” Journal of Nuclear Medicine, vol. 50, no. 7, pp. 1153–1160, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus